Prexton Therapeutics is dedicated to developing innovative drugs aimed at improving the quality of life for individuals suffering from brain disorders and other diseases. The company specializes in designing novel mGluR4 compounds, which are a new class of treatments for these conditions. Prexton Therapeutics primarily serves patients with neurological disorders, operating within the pharmaceutical and biotech market. The business model revolves around research and development of proprietary compounds, which are then licensed or sold to larger pharmaceutical companies for further development and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from sales of the developed drugs.

Keywords: mGluR4, brain disorders, neurological, innovative drugs, biotech, pharmaceutical, R&D, licensing, proprietary compounds, quality of life.